26 cents or 27 cents on $53 million revs. They may write down some depreciation, though to lower taxes, this may affect earnings.. EBITA reading should be good.
I see there are 10.6 million outstanding shares currently. Maybe I missed something. 2 million new shares sounds about right, not sure about open market sale, though.
We all knew they needed money per CEO comments, that is fine, several stocks have done offerings recently and performed fairly well.
Yes, some strange things on the board, I've been trying to figure out where this pam palmer fits in, nobody wants to reply to that one.
LOL, why are you so keen on where this old man ate and slept? Maybe you two actually ran into each other. Just messing with ya.
Failure Talk, what is this? Looks like you need an eye exam. Stock is slowly gaining will bullish chart pattern.
When did you learn about this FDA guru, before or after you lost huge on PTIE, or you having dinner under the bonnet with him? If this strategy is a problem, they should pull the other gadget off the market, who knows how many Tylox and other pills are making their way to the street with the Avancen device?
Yes, those who don't listen to the "big cat" usually get burnt. Thanks Schroe and Siamese cat. The cat has a big following, I buy what the cat buys.
This is a better way to dispense. Device keeps track of all pills given out, electronic format. No cart for nurse to have to go and get a pill out of. Carts are where diversion can happen, a nurse can get a pill out and just say they gave to patient, and not do it to divert. Zalviso keeps track of everything.
Herky, if you read the patents on Zalviso system, you will note that a Dr. or nurse can supervise patients to help them with the device. Ie- they can help them put the device to mouth and put thumb in the reader. This should be part of the REMS and IFU, to help patients learn the device or if the are too "groggy" as some say to operate alone. This alone would help in resubmission, IMO. Stability and optical errors should be easy to address.